<DOC>
	<DOCNO>NCT01539317</DOCNO>
	<brief_summary>The purpose protocol determine whether pain sexual intercourse reduce menopausal , breast cancer survivor evaluate effectiveness non-hormonal therapy ( Lidocaine Liquid ) vs. placebo liquid reduce pain . The investigator hypothesize pain arises vulvar vestibule . The investigator predict localize use lidocaine efficacious use placebo liquid .</brief_summary>
	<brief_title>Therapy Prevent Sexual Pain Breast Cancer Survivors</brief_title>
	<detailed_description>For study three visit 3 month period . Subjects undergo gynecological exam screen visit determine severity pain associate uncomfortable intercourse . A touch test use Q-tips use screen exam subject report pain application study drug placebo . Subjects also report pain tampon test . A sample vaginal cell liquid obtain screen visit PI rule possible infection , disease , disorder . PI also show subject area vestibule mirror subject apply study drug home properly . Subjects fill 4 questionnaire medical health history , cancer history , pain , distress sexual activity . Subject give supply either study drug placebo take home . The first visit last approximately 2 hour . Subjects return second visit 4 week third visit 8 week diary review , questionnaire , examination . The second third visit examination repeat examination do first visit , comparison placebo , PI use study drug touch test . The second third visit last approximately 1 hour . Subjects fill questionnaire throughout study participation . Topics include ; medical health history , cancer history , pain , distress sexual activity . Subjects also fill diary chart tampon test complete home , sexual activity perform , pain level study drug application day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vulvodynia</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Eligibility Criteria 1 . Women age 18 70 year old . 2 . Has previous diagnosis breast cancer ( ductal lobular carcinoma , invasive ) . 3 . 1 year diagnosis breast cancer . 4 . Stable heterosexual partnership =/ &gt; 5 year investigator discretion . 5 . More 6 month consistent insertional pain intercourse ( may stop intercourse due consistent experience pain ) . 6 . Menopausal , demonstrate least one following : i. cessation menses 1 year ii . Bilateral oophorectomy iii . Follicle Stimulating Hormone ( FSH ) level &gt; 25 woman age 50 ovary scar absent uterus ( acceptable FSH level infer woman 's oncologist monitor FSH aromatase inhibitor therapy ) . 7 . Willingness enter study compare topical placebo liquid topical liquid lidocaine . 8 . Willingness evaluate liquid use tampon test many 4 time per month , willingness attempt intercourse tampon test indicate tolerable penetrative pain . 3.2 Exclusion Criteria 1 . Diagnosis benign malignant phyllode tumor breast . 2 . Consistently pain pelvis low abdomen intercourse ( deep dyspareunia ) . 3 . Has develop shrinkage vaginal opening vaginal length point small succeed vaginal penetration partner ( also assess clinical exam ) . 4 . Partner problem sexual dysfunction limit performance making inconsistent . 5 . The potential subject partner serious current medical condition might interrupt completion 6 month study . 6 . Potential subject diagnose physical therapist significant pelvic floor muscle dysfunction cause pain ( pelvic floor myalgia ) . 7 . Potential subject use topical systemic estrogen within last 4 month . 8 . Has continue tenderness vestibule mucosa immediately application test liquid . 9 . Allergy lidocaine numbing agent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Vulvodynia</keyword>
	<keyword>Dyspareunia</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Menopause</keyword>
	<keyword>Vaginal dryness</keyword>
	<keyword>Painful intercourse</keyword>
</DOC>